SG10201401976YA - Uses of immunoconjugates targeting cd138 - Google Patents

Uses of immunoconjugates targeting cd138

Info

Publication number
SG10201401976YA
SG10201401976YA SG10201401976YA SG10201401976YA SG10201401976YA SG 10201401976Y A SG10201401976Y A SG 10201401976YA SG 10201401976Y A SG10201401976Y A SG 10201401976YA SG 10201401976Y A SG10201401976Y A SG 10201401976YA SG 10201401976Y A SG10201401976Y A SG 10201401976YA
Authority
SG
Singapore
Prior art keywords
immunoconjugates targeting
immunoconjugates
targeting
Prior art date
Application number
SG10201401976YA
Inventor
Frank Osterroth
Christoph Uherek
Christoph Bruecher
Benjamin Daelken
André Engling
Thomas Haeder
Andrea Wartenberg-Demand
Gabriele Niemann
Chantal Zuber
Niklas Czeloth
Silke Aigner
Steffen Zeng
Gregor Schulz
Original Assignee
Biotest Ag
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest Ag, Immunogen Inc filed Critical Biotest Ag
Publication of SG10201401976YA publication Critical patent/SG10201401976YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
SG10201401976YA 2009-05-06 2010-05-05 Uses of immunoconjugates targeting cd138 SG10201401976YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17606909P 2009-05-06 2009-05-06
US25943009P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
SG10201401976YA true SG10201401976YA (en) 2014-10-30

Family

ID=42752045

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201401976YA SG10201401976YA (en) 2009-05-06 2010-05-05 Uses of immunoconjugates targeting cd138
SG2011080132A SG175421A1 (en) 2009-05-06 2010-05-05 Uses of immunoconjugates targeting cd138

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011080132A SG175421A1 (en) 2009-05-06 2010-05-05 Uses of immunoconjugates targeting cd138

Country Status (16)

Country Link
US (1) US9289509B2 (en)
EP (1) EP2427216B1 (en)
JP (2) JP2012526079A (en)
KR (1) KR101725170B1 (en)
CN (1) CN102573916B (en)
AU (1) AU2010244428B2 (en)
BR (1) BRPI1013990A2 (en)
CA (1) CA2761120A1 (en)
ES (1) ES2726022T3 (en)
IL (1) IL216166A0 (en)
MX (2) MX2011011684A (en)
NZ (2) NZ613647A (en)
RU (2) RU2015128833A (en)
SG (2) SG10201401976YA (en)
WO (1) WO2010128087A2 (en)
ZA (1) ZA201108341B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045877A1 (en) 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CN108129573B (en) 2007-09-21 2021-10-08 加利福尼亚大学董事会 Targeted interferons exhibit potent apoptotic and antitumor activity
MX2010007101A (en) * 2007-12-26 2011-07-01 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells.
HUE024291T2 (en) * 2007-12-26 2016-01-28 Biotest Ag Immunoconjugates targeting cd138 and uses thereof
ES2475201T3 (en) 2007-12-26 2014-07-10 Biotest Ag Agents directed against CD138 and their uses
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
CN104302324A (en) * 2011-12-08 2015-01-21 生物测试股份公司 Uses of immunoconjugates targeting cd138
CA2866881A1 (en) * 2012-03-09 2013-09-12 Lankenau Institute For Medical Research Compositions and methods for treating cancer
RS58921B1 (en) 2012-10-12 2019-08-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US9803021B2 (en) * 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
EA201591219A1 (en) * 2012-12-27 2015-12-30 Санофи ANTIBODIES AGAINST LAMP1 AND CONJUGATES ANTIBODIES AND MEDICINES AND THEIR APPLICATION
MX362970B (en) 2013-03-13 2019-02-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
RU2670127C2 (en) * 2013-03-13 2018-10-18 Санофи Compositions comprising antibody to cd38 and carfilzomib
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
AU2015204766B2 (en) * 2014-01-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
GB2526139A (en) * 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
DK3160513T3 (en) 2014-06-30 2020-04-06 Glykos Finland Oy SACCHARIDE DERIVATIVES OF A TOXIC PAYLOAD AND ANTIBODY CONJUGATES THEREOF
SG11201701328XA (en) * 2014-09-02 2017-03-30 Immunogen Inc Methods for formulating antibody drug conjugate compositions
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CN110198703A (en) 2016-11-21 2019-09-03 艾里奥治疗公司 The transdermal delivery of big reagent
WO2018199176A1 (en) 2017-04-26 2018-11-01 Mitsubishi Tanabe Pharma Corporation Syndecan-1 (cd138) binding agents and uses thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
CA3074032A1 (en) 2017-10-02 2019-04-11 Visterra, Inc. Antibody molecules to cd138 and uses thereof
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019224275A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN112279917B (en) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 Monoclonal antibody of mouse anti-cell surface glycoprotein CD138 capable of being applied to tumor cell capture
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2023019204A2 (en) * 2021-08-11 2023-02-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or characterizing hematological malignancies and precursor conditions
KR20230049463A (en) * 2021-10-06 2023-04-13 주식회사 이뮤노로지컬디자이닝랩 Recombinant protein which recognizes CD138 and the composition comprising the same for treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5612016A (en) 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US6080777A (en) 1992-01-31 2000-06-27 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
US6087362A (en) 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1507557A4 (en) 2002-04-23 2006-06-14 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
PL222222B1 (en) 2003-01-22 2016-07-29 Glycart Biotechnology Ag Method for polypeptide production
EP1627081A4 (en) 2003-05-02 2006-08-16 Health Research Inc Use of jag2 expression in diagnosis of plasma cell disorders
JP2007501021A (en) * 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド Antibodies and fusion proteins containing genetically engineered constant regions
MXPA06000830A (en) 2003-07-21 2006-04-18 Immunogen Inc A ca6 antigen-specific cytotoxic conjugate and methods of using the same.
US20060045877A1 (en) 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
CN101223120A (en) * 2005-02-23 2008-07-16 杰克·L·阿比瑟 Honokiol derivatives for the treatment of proliferative disorders
CA2600712A1 (en) 2005-03-14 2006-09-21 Immunomedics, Inc. Methods of treating cancer using ppar-gamma antagonists
EA015584B1 (en) * 2005-03-23 2011-10-31 Генмаб А/С Antibody to human cd38 and use thereof
BRPI0619460A2 (en) 2005-12-06 2011-11-08 Domantis Ltd ligand, ligand use, composition, drug dispensing device, isolated or recombinant nucleic acid, vector, host cell, and method for producing a ligand
CN101370831B (en) * 2006-01-13 2013-06-19 Irm责任有限公司 Methods and compositions for treating allergic diseases
EP2015772A2 (en) * 2006-05-03 2009-01-21 Elke Pogge Von Strandmann Agent for the treatment of malignant diseases
CN101820911B (en) * 2007-06-12 2015-05-06 Ac免疫有限公司 Humanized antibodies to amyloid beta
EP2178370A4 (en) * 2007-07-17 2011-01-12 Zalicus Inc Combinations for the treatment of b-cell proliferative disorders
MX2010007101A (en) * 2007-12-26 2011-07-01 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells.
ES2475201T3 (en) * 2007-12-26 2014-07-10 Biotest Ag Agents directed against CD138 and their uses
JP2011507933A (en) * 2007-12-26 2011-03-10 バイオテスト・アクチエンゲゼルシヤフト Methods for reducing cytotoxic side effects and improving efficacy of immune complexes
HUE024291T2 (en) 2007-12-26 2016-01-28 Biotest Ag Immunoconjugates targeting cd138 and uses thereof
AU2009271401A1 (en) * 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects

Also Published As

Publication number Publication date
NZ596807A (en) 2013-09-27
NZ613647A (en) 2015-02-27
WO2010128087A2 (en) 2010-11-11
ZA201108341B (en) 2019-07-31
RU2015128833A3 (en) 2019-03-01
SG175421A1 (en) 2011-12-29
JP6165213B2 (en) 2017-07-19
EP2427216A2 (en) 2012-03-14
RU2011149471A (en) 2013-06-20
RU2015128833A (en) 2015-11-10
KR101725170B1 (en) 2017-04-10
KR20120047209A (en) 2012-05-11
IL216166A0 (en) 2012-01-31
JP2016053053A (en) 2016-04-14
RU2561041C2 (en) 2015-08-20
JP2012526079A (en) 2012-10-25
ES2726022T3 (en) 2019-10-01
BRPI1013990A2 (en) 2019-04-30
CA2761120A1 (en) 2010-11-11
AU2010244428A1 (en) 2011-12-15
US9289509B2 (en) 2016-03-22
WO2010128087A3 (en) 2011-01-27
CN102573916A (en) 2012-07-11
MX345953B (en) 2017-01-27
MX2011011684A (en) 2012-01-20
CN102573916B (en) 2017-05-17
US20110123554A1 (en) 2011-05-26
AU2010244428B2 (en) 2015-01-29
EP2427216B1 (en) 2019-02-20
WO2010128087A9 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
ZA201108341B (en) Uses of immunoconjugates targeting cd138
HK1253715A1 (en) Targeted conjugates of pyrrolobenzodiazepines
IL252864B (en) Targeted pyrrolobenzodiazapine conjugates
HK1169318A1 (en) Targeted immunoconjugates
GB0918579D0 (en) Gadd45beta targeting agents
ZA201106050B (en) Dye-polymers formulations
EP2577586A4 (en) Event-based ad targeting
EP2504020A4 (en) Formulations of daptomycin
IL269369A (en) Improved formulations
HK1203053A1 (en) Uses of immunoconjugates targeting cd138 cd138
SI3338807T1 (en) Targeting construct for gas-filled microvesicles
GB0919210D0 (en) Formulations
EP2424875A4 (en) Purification of immunoconjugates
EP2461850A4 (en) Targeting therapeutic agents
ZA201108277B (en) Use of altitude-compensating nozzle
EP2558506A4 (en) Tissue targeting
PL2407155T3 (en) Formulations of inecalcitol
GB0910078D0 (en) Uses of mannose-6-phosphate
GB201010500D0 (en) Therapeutic conjugates
IL217390A0 (en) Formulations
EP2459540A4 (en) Preparation of fipamezole
GB0917656D0 (en) Midification of assembled conduit
GB0915468D0 (en) Get me out of here
GB0914489D0 (en) Improved formulations
HK1167317A1 (en) Improved pharmacokinetics of s-adenosylmethionine formulations s-